PURPOSE The administration of recombinant human growth hormone in adults with growth hormone deficiency has been known to improve metabolic impairment and quality of life. Patients, however, have to tolerate daily injections of growth hormone. The efficacy, safety, and compliance of weekly administered sustained-release recombinant human growth hormone (SR-rhGH, Declage™) supplement in patients...

Background/Aims: Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) both contribute to growth. To determine if recombinant human (rh)GH + rhIGF-1 therapy is more effective than rhGH alone to treat short stature, we assessed the efficacy and safety of coadministered rhGH + rhIGF-1 in short children with GH sufficiency and low IGF-1. Methods: In a 3-year, randomized, multicenter, open-l...

In adolescents with cystic fibrosis (CF) the anabolic benefits of resistance exercise (RT) on skeletal muscle hypertrophy may synergize with recombinant human growth hormone (rhGH) therapy exerting an effect greater than either alone. We present a male adolescent with CF taking rhGH, who began RT. During rhGH alone, weight, height and BMI increased 14, 12 and 10 centiles (21st, 21st, 26th), res...

Congenital combined pituitary hormone deficiency (CPHD) is associated with deficiencies of anterior pituitary hormones. PROP1 gene mutations are often responsible for CPHD, but few such cases have been reported in Japan. This study describes a 37-year-old Japanese man with CPHD, treated with hydrocortisone, testosterone, and L-thyroxine, who was evaluated for adult growth hormone deficiency (GH...

Local lipohypertrophy due to recombinant human growth hormone (rhGH) administration is a rare phenomenon. Here, we report a case of an 11-year-old girl who presented with a paraumbilical swelling, approximately one year after the start of rhGH treatment for short stature due to the presumed diagnosis of partial growth hormone insensitivity. Ultrasound imaging revealed an asymmetric distribution...

Background Data During the last decade, we have used recombinant human growth hormone (rhGH; 0.2 mg/kg/day SQ) to successfully treat 130 children with more than 40% total body surface area (TBSA) burns to enhance wound healing and decrease protein loss. A significant increase in the mortality of adult patients in the intensive care unit who were given rhGH has recently been reported in two larg...

We studied the expression of human growth hormone (hGH) in E. coli under a bacteriophage T5-base promoter in a pQE30 expression vector. For an efficient expression of hGH cDNA, a number of codons at the hGH N-terminal coding region were altered based on the E. coli major codons. An over-expression of hGH in the bacteria, carrying the recombinant plasmids, was observed at 37°C in the presence of...

we studied the expression of human growth hormone (hgh) in e. coli under a bacteriophage t5-base promoter in a pqe30 expression vector. for an efficient expression of hgh cdna, a number of codons at the hgh n-terminal coding region were altered based on the e. coli major codons. an over-expression of hgh in the bacteria, carrying the recombinant plasmids, was observed at 37°c in the presence of...

cell lines derived from mammalian are dominant systems for the production of recombinant therapeutic proteins because of their capacity for correct protein folding, assembly and post-translational modification. in the search of an efficient method for the production of  a recombinant protein using animal cell culture, we investigated the effects of different treatment including fetal calf serum...